Overview

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins